Analyst Hikes and 11% Surge Cap Charles River's Strong Q2 Week
CRL sits 85% above its 52-week low of $144.26.
Summary
Charles River's Q2 beat and raised guidance triggered a wave of analyst upgrades, with Morgan Stanley, RBC, Evercore, and JPMorgan lifting price targets as high as $310. The stock surged over 11% for the week, reflecting renewed confidence in biotech spending recovery. This follows the August 5th earnings release that showed $1B in revenue, $3.02 non-GAAP EPS, and a $701M bookings jump—the highest in nearly four years. The market is pricing in sustained demand momentum.
At the time of this announcement, CRL was trading at $267.49 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12.8B. The 52-week trading range was $144.26 to $268.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.